<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-4157</journal-id>
<journal-title><![CDATA[Biomédica]]></journal-title>
<abbrev-journal-title><![CDATA[Biomédica]]></abbrev-journal-title>
<issn>0120-4157</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-41572017000100096</article-id>
<article-id pub-id-type="doi">10.7705/biomedica.v37i2.3204</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Prevalencia de la resistencia de Mycobacterium tuberculosis a quinolonas y fármacos inyectables en Colombia, 2012-2013]]></article-title>
<article-title xml:lang="en"><![CDATA[Prevalence of Mycobacterium tuberculosis resistance to quinolones and injectables in Colombia, 2012-2013]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llerena]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zabaleta]]></surname>
<given-names><![CDATA[Angie]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valbuena]]></surname>
<given-names><![CDATA[Angélica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Murcia]]></surname>
<given-names><![CDATA[Martha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Salud Subdirección Laboratorio Nacional de Referencia Laboratorio de Micobacterias]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Colombia Facultad de Medicina Departamento de Microbiología]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>01</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>01</month>
<year>2017</year>
</pub-date>
<volume>37</volume>
<numero>1</numero>
<fpage>96</fpage>
<lpage>103</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-41572017000100096&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-41572017000100096&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-41572017000100096&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La tuberculosis es un problema de salud pública a nivel mundial. En 2014, la Organización Mundial de la Salud estimó que se habían presentado 9,6 millones de casos nuevos y 480.000 multirresistentes. La evaluación de la resistencia a fármacos inyectables y a quinolonas se introdujo hace pocos años, por lo cual no se conoce su prevalencia.  Objetivo: Determinar la prevalencia de la resistencia a amicacina, kanamicina, capreomicina y ofloxacina en casos de tuberculosis resistente a isoniacida, rifampicina o a ambas, entre 2012 y 2013.  Materiales y métodos: Se hizo un estudio de corte transversal con 489 aislamientos resistentes a isoniacida o rifampicina. Las pruebas de sensibilidad se hicieron con la técnica Bactec MGITTM. Para el análisis de la proporción de la resistencia, los casos se agruparon según el antecedente de tratamiento con medicamentos de segunda línea.  Resultados: En los 438 casos nuevos, la resistencia global a la kanamicina fue mayor (7,1 %; IC95% 4,6-9,6); en los 51 casos previamente tratados, dicha resistencia fue de 27,5 % (IC95% 14,2-40,7). La resistencia global fue mayor en casos con antecedentes de tratamiento con quinolonas y fármacos inyectables. Se encontraron siete casos de tuberculosis extremadamente resistente.  Conclusión: El estudio evidenció la presencia de resistencia a fármacos de segunda línea en personas con tuberculosis farmacorresistente sin tratamiento previo o tratadas previamente con quinolonas o fármacos inyectables, estos últimos con mayor porcentaje de resistencia. En consecuencia, es esencial practicar rutinariamente las pruebas de sensibilidad y el análisis de esta información.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Tuberculosis is a health problem worldwide. The World Health Organization estimated 9.6 million new cases and 480,000 multirresistant cases for 2014. The assessment of resistance to quinolones and injectables was implemented only a few years ago, so its prevalence is not known.  Objective: To determine the prevalence of resistance to amikacin, capreomycin and ofloxacin in cases of tuberculosis resistant to isoniazid and/or rifampin during 2012-2013.  Materials and methods: This was a cross-sectional study of 489 isolates resistant to isoniazid and/or rifampin. We used the Bactec MGITTM technique for susceptibility tests. For analyzing the rate of resistance, we grouped cases according to the history of treatment with second line drugs.  Results: In the 438 new cases, the drug that showed greater overall resistance was kanamycin with 7.1 % (95% CI: 4.6 to 9.6). In 51 previously treated cases, this highest resistance was 27.5 % (95% CI: 14.2 to 40.7). The overall resistance was higher in cases with a history of treatment with quinolones and injectables. We found seven cases of extremely resistant tuberculosis.  Conclusion: This study demonstrates the presence of resistance to second line drugs in people with drug-resistant tuberculosis with and without previous treatment with quinolones and/or injectables, these latter having a higher percentage of resistance. For that reason, it is essential to perform susceptibility testing and analyze this information routinely.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Mycobacterium tuberculosis]]></kwd>
<kwd lng="es"><![CDATA[tuberculosis resistente a múltiples medicamentos]]></kwd>
<kwd lng="es"><![CDATA[tuberculosis extremadamente resistente a drogas]]></kwd>
<kwd lng="es"><![CDATA[isoniazida]]></kwd>
<kwd lng="es"><![CDATA[rifampin]]></kwd>
<kwd lng="es"><![CDATA[Colombia]]></kwd>
<kwd lng="en"><![CDATA[Mycobacterium tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[tuberculosis, multidrug-resistant]]></kwd>
<kwd lng="en"><![CDATA[MDR tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[extensively drug-resistant tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[isoniazid]]></kwd>
<kwd lng="en"><![CDATA[rifampin]]></kwd>
<kwd lng="en"><![CDATA[Colombia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[What is DOT? A guide to understanding the WHO-recommended TB control strategy known as DOTS]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Plan Mundial para Detener la Tuberculosis, 2006-2015]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Global tuberculosis control: Surveillance, planning, financing]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Global tuberculosis control WHO report]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<collab>Instituto Nacional de Salud</collab>
<source><![CDATA[Informe final. Tuberculosis, Colombia]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<collab>Instituto Nacional de Salud</collab>
<source><![CDATA[Tuberculosis farmacorresistente. Nuevo evento de notificación obligatoria. Código 825]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<collab>Clinical and Laboratory Standards Institute</collab>
<source><![CDATA[Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes. Approved standard]]></source>
<year>2011</year>
<edition>Second Edition</edition>
<publisher-loc><![CDATA[Wayne ]]></publisher-loc>
<publisher-name><![CDATA[CLSI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="book">
<collab>Becton Dickinson</collab>
<source><![CDATA[Inserto, técnica de MGIT 960(r) para evaluación de resistencia a fármacos antituberculosos]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Heidelberg ]]></publisher-loc>
<publisher-name><![CDATA[Becton Dickinson]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<collab>Becton Dickinson</collab>
<source><![CDATA[Manual Epicenter, técnica de MGIT 960(r) para evaluación de resistencia a fármacos antituberculosos]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Heidelberg ]]></publisher-loc>
<publisher-name><![CDATA[Becton Dickinson]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Likelihood of generating MDR-TB and XDRTB under adequate national tuberculosis control programme implementation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caminero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>2008</year>
<volume>12</volume>
<page-range>869-77</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multidrug-resistant tuberculosis: Epidemiology, risk factor and case finding]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caminero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>2010</year>
<volume>14</volume>
<page-range>382-90</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Awad]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dennis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Varón]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Lineamiento para el manejo programático de pacientes con tuberculosis farmacorresistente]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Circular 001 del 8 de enero de 2013. Lineamientos para el manejo programático de los medicamentos de segunda línea para tuberculosis farmacorresistente en Colombia]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antibiotic susceptibility patterns of Mycobacterium tuberculosis isolates from Guizhou province of China against 13 antituberculosis drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Microb Drug Resist]]></source>
<year>2015</year>
<volume>21</volume>
<page-range>292-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nafees]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arshad]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Izaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Braz J Infect Dis]]></source>
<year>2016</year>
<volume>20</volume>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jabeen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shakoor]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Malik]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hasan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Mycobacteriol]]></source>
<year>2015</year>
<volume>4</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>47-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Resistance patterns among multidrugresistant tuberculosis patients in greater metropolitan Mumbai: Trends over time]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dalal A]]></surname>
<given-names><![CDATA[Pawaskar A]]></given-names>
</name>
<name>
<surname><![CDATA[DasM]]></surname>
<given-names><![CDATA[Desai R]]></given-names>
</name>
<name>
<surname><![CDATA[Prabhudesai P]]></surname>
<given-names><![CDATA[Chhajed]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<page-range>e0116798</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Acquired drug resistance in Mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kempker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kipiani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mirtskhulava]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tukvadze]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Magee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Blumberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Emerg Infect Dis]]></source>
<year>2015</year>
<volume>21</volume>
<page-range>992-1001</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vigilancia nacional de la resistencia a medicamentos antituberculosos, Perú, 2005-2006]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asencios]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Quispe]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vásquez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Perú Med Exp Salud Pública]]></source>
<year>2009</year>
<volume>26</volume>
<page-range>278-87</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemia de tuberculosis multidrogo resistente y extensivamente resistente a drogas (TB MDR/XDR) en el Perú: situación y propuestas para su control]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Castillo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saravia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Somocurcio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Perú Med Exp Salud Pública]]></source>
<year>2009</year>
<volume>26</volume>
<page-range>380-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Resistencia a drogas de segunda línea en cepas peruanas de Mycobacterium tuberculosis multidrogorresistentes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barletta]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zamudio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rigouts]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Perú Med Exp Salud Pública]]></source>
<year>2014</year>
<volume>31</volume>
<page-range>676-82</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to firstand second-line drugs: An individual patient data metaanalysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bastos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Weyer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Leimane]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2014</year>
<volume>59</volume>
<page-range>1364-74</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fluoroquinolone resistance in non-multidrug-resistant tuberculosis a surveillance study in New South Wales, Australia, and a review of global resistance rates]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jelfs]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sintchenko]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Infect Dis]]></source>
<year>2014</year>
<volume>26</volume>
<page-range>149-53</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[The shorter MDR-TB regimen]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Tuberculosis diagnostics molecular line-probe assay for the detection of resistance to second-line anti-TB drugs (SL-LPA)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Quinolonas. Perspectivas actuales y mecanismos de resistencia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Garza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Chil Infectol]]></source>
<year>2015</year>
<volume>32</volume>
<page-range>499-504</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fluoroquinolone-resistant tuberculosis: Implications in settings with weak healthcare systems]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jabeen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shakoor]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hasan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Infect Dis]]></source>
<year>2015</year>
<volume>32</volume>
<page-range>118-23</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
